BGI
NRXP icon

B Group Inc’s NRX Pharmaceuticals NRXP Stock Holding History

B Group Inc’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7M Buy
4,091,767
+1,091,767
+36% +$3.61M 7.86% 4
2026
Q1 		$6.39M Buy
+3,000,000
New +$6.06M 4.74% 7

Other funds holding NRXP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

B Group Inc's NRXP Position: Q2 2026 in Review

B Group Inc increased its NRX Pharmaceuticals (NRXP) stake by 36% in Q2 2026, buying an estimated $3.61M and bringing the position to 4,091,767 shares worth $16.7M. The position accounts for 7.86% of the portfolio, ranked #4.

B Group Inc first reported a position in NRXP in Q1 2026 and has held it in 2 quarters since. 47 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • B Group Inc held 4,091,767 shares of NRX Pharmaceuticals worth $16.7M as of Q2 2026.
  • B Group Inc bought 1,091,767 NRX Pharmaceuticals shares in Q2 2026, an estimated $3.61M.
  • NRX Pharmaceuticals made up 7.86% of B Group Inc's portfolio in Q2 2026, its #4 holding.
  • B Group Inc first reported a position in NRX Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 47 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on B Group Inc's 13F filing for Q2 2026, filed 14 Aug 2026.